Jonathan McAleese
Overview
Explore the profile of Jonathan McAleese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hill N, Hanna G, Walls G, McAleese J
JTO Clin Res Rep
. 2024 Dec;
5(12):100739.
PMID: 39735887
No abstract available.
2.
Walls G, Hill N, McMahon M, Kearney B, McCann C, McKavanagh P, et al.
JACC CardioOncol
. 2024 Sep;
6(4):529-540.
PMID: 39239328
Background: Radiation-induced cardiotoxicity poses a significant challenge in lung cancer management because of the close anatomical proximity of the heart to the lungs, compounded by a high prevalence of cardiovascular...
3.
Walls G, McCann C, OConnor J, OSullivan A, I Johnston D, McAleese J, et al.
Radiother Oncol
. 2024 Jan;
192:110085.
PMID: 38184145
Background And Purpose: Symptomatic arrhythmia is common following radiotherapy for non-small cell lung cancer (NSCLC), frequently resulting in morbidity and hospitalization. Modern treatment planning technology theoretically allows sparing of cardiac...
4.
Ali A, Greenwood J, Walls G, Belshaw L, Agnew C, McAleese J, et al.
Br J Radiol
. 2023 Jul;
96(1149):20220461.
PMID: 37393541
Objective: This study aims to analyse lung tumour motion and to investigate the correlation between the internal tumour motion acquired from four-dimensional computed tomography (4DCT) and the motion of an...
5.
Walls G, McMahon M, Moore N, Nicol P, Bradley G, Whitten G, et al.
BJR Open
. 2023 Jun;
5(1):20220049.
PMID: 37389005
Objective: Interstitial lung disease (ILD) is relatively common in patients with lung cancer with an incidence of 7.5%. Historically pre-existing ILD was a contraindication to radical radiotherapy owing to increased...
6.
Walls G, OConnor J, Harbinson M, McCarron E, Duane F, McCann C, et al.
Radiother Oncol
. 2023 Jun;
186:109762.
PMID: 37348608
Introduction: Radiation cardiotoxicity is a dose-limiting toxicity and major survivorship issue for patients with non-small cell lung cancer (NSCLC) completing curative-intent radiotherapy, however patients' cardiovascular baseline is not routinely optimised...
7.
Walls G, McCann C, Ball P, Atkins K, Mak R, Bedair A, et al.
Radiother Oncol
. 2023 Apr;
184:109680.
PMID: 37105303
Background And Purpose: Cardiac arrhythmia is a recognised potential complication of thoracic radiotherapy, but the responsible cardiac substructures for arrhythmogenesis have not been identified. Arrhythmogenic tissue is commonly located in...
8.
Lynch C, Harrison S, Butler J, Baldwin D, Dawkins P, van der Horst J, et al.
Cancer Control
. 2022 Oct;
29:10732748221119354.
PMID: 36269109
Background: Research from the International Cancer Benchmarking Partnership (ICBP) demonstrates that international variation in lung cancer survival persists, particularly within early stage disease. There is a lack of international consensus...
9.
Singh U, Walls G, Hanna G, Lynch T, McAleese J
J Med Imaging Radiat Oncol
. 2020 Oct;
65(1):92-94.
PMID: 33103346
Stereotactic ablative radiotherapy offers a radical treatment approach for early stage lung cancers and an aggressive local therapy for pulmonary oligometastases from other tumour sites. Chest wall toxicity is one...
10.
Manoharan P, Salem A, Mistry H, Gornall M, Harden S, Julyan P, et al.
J Thorac Oncol
. 2019 Apr;
14(7):1296-1305.
PMID: 31002954
Introduction: We used phase-3 CONVERT trial data to investigate the impact of fludeoxyglucose F 18 (F-FDG) positron emission tomography (PET)/computed tomography (CT) in SCLC. Methods: CONVERT randomized patients with limited-stage...